Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S15-9. doi: 10.1016/j.urolonc.2011.09.003. Epub 2011 Oct 19.
Prostate cancer (CaP) continues to be a significant burden on men's health. While significant advances have been made in the diagnosis and treatment of localized disease, androgen deprivation therapy remains the treatment of choice for advanced and metastatic disease. However, once a man progresses on androgen deprivation, therapies targeting castration-resistant CaP have been extremely limited until quite recently. Urologic oncologists who wish to play an active role in the treatment of men with CaP from diagnosis through end-of-life care should be familiar with administration of and toxicities associated with chemotherapeutic agents. This review is directed at urologists and urologic oncologists and will discuss many of the FDA-approved intravenous agents currently available for castration-resistant CaP with a specific focus on the side-effects associated with these regimens.
前列腺癌（CaP）仍然是男性健康的重大负担。尽管在局部疾病的诊断和治疗方面取得了重大进展，但雄激素剥夺疗法仍然是晚期和转移性疾病的治疗选择。然而，一旦男性进展为雄激素剥夺，针对去势抵抗性 CaP 的治疗方法一直非常有限，直到最近才有所改善。希望在从诊断到临终关怀的整个阶段积极参与 CaP 男性治疗的泌尿外科医生应该熟悉化疗药物的使用和相关毒性。本综述面向泌尿科医生和泌尿科肿瘤学家，将讨论目前许多获得 FDA 批准的用于去势抵抗性 CaP 的静脉内药物，并特别关注这些方案相关的副作用。
